Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma

Br J Dermatol. 2021 Feb;184(2):354-356. doi: 10.1111/bjd.19490. Epub 2020 Sep 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Lymphoma, B-Cell* / drug therapy
  • Rituximab / therapeutic use
  • Skin Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Rituximab